These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 11466511)

  • 21. Histopathological characteristics of post kala-azar dermal leishmaniasis: a series of 88 patients.
    Singh A; Ramesh V; Ramam M
    Indian J Dermatol Venereol Leprol; 2015; 81(1):29-34. PubMed ID: 25566893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. History of kala-azar in India. 1947.
    Sen Gupta BC
    Indian J Med Res; 2006 Mar; 123(3):281-6. PubMed ID: 16789340
    [No Abstract]   [Full Text] [Related]  

  • 23. Visceral kala-azar associated with post-kala-azar dermal leishmaniasis.
    Singh NK; Agrawal SK; Jha TK
    J Assoc Physicians India; 1989 Feb; 37(2):191. PubMed ID: 2808294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sir Leonard Rogers, FRS (1868-1962) and his papers.
    Sheppard J
    Med Hist; 1983 Apr; 27(2):214-5. PubMed ID: 6345969
    [No Abstract]   [Full Text] [Related]  

  • 25. Chemotherapy of antimonial compounds in kala-azar infection. Part IV. Further observations on the therapeutic values of urea stibamine. By U.N. Brahmachari, 1922.
    Brahmachari UN
    Indian J Med Res; 1989 Jan; 89():393-404. PubMed ID: 2644171
    [No Abstract]   [Full Text] [Related]  

  • 26. Noninvasive management of Indian visceral leishmaniasis: clinical application of diagnosis by K39 antigen strip testing at a kala-azar referral unit.
    Sundar S; Sahu M; Mehta H; Gupta A; Kohli U; Rai M; Berman JD; Murray HW
    Clin Infect Dis; 2002 Sep; 35(5):581-6. PubMed ID: 12173133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cutaneous and visceral leishmaniasis: a historical perspective.
    Hart DT
    Trans R Soc Trop Med Hyg; 1985; 79(5):740-1. PubMed ID: 3913073
    [No Abstract]   [Full Text] [Related]  

  • 28. [Diseases of the digestive tract in patients returning from the tropics].
    FERNEX M
    Schweiz Med Wochenschr; 1962 Oct; 92():1239-44. PubMed ID: 13944811
    [No Abstract]   [Full Text] [Related]  

  • 29. Post-kala-azar dermal leishmaniasis.
    Baghestani S; Handjani F; Sodeifi M; Kumar PV
    Eur J Dermatol; 1998 Jun; 8(4):277-9. PubMed ID: 9649686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increasing incidence of post-kala-azar dermal leishmaniasis in a population-based study in Bangladesh.
    Rahman KM; Islam S; Rahman MW; Kenah E; Ghalib CM; Zahid MM; Maguire J; Rahman M; Haque R; Luby SP; Bern C
    Clin Infect Dis; 2010 Jan; 50(1):73-6. PubMed ID: 19951168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. William Boog Leishman-A Brief Reminder of His Life and Work on the Occasion of His 150th Birthday.
    Weyers W
    Am J Dermatopathol; 2016 Jun; 38(6):436-43. PubMed ID: 27205906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
    Berman JD; Badaro R; Thakur CP; Wasunna KM; Behbehani K; Davidson R; Kuzoe F; Pang L; Weerasuriya K; Bryceson AD
    Bull World Health Organ; 1998; 76(1):25-32. PubMed ID: 9615494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The overexpression of genes of thiol metabolism contribute to drug resistance in clinical isolates of visceral leishmaniasis (kala azar) in India.
    Singh N; Chatterjee M; Sundar S
    Parasit Vectors; 2014 Dec; 7():596. PubMed ID: 25515494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Bagdad boil deploys to the United States.
    Aronson SM
    Med Health R I; 2007 Aug; 90(8):231. PubMed ID: 17867404
    [No Abstract]   [Full Text] [Related]  

  • 35. [Kala-azar in immunosuppressed patients. Apropos of a case disclosed by skin lesions].
    Frances C; Merle Beral H; Franceschini P; Lessana-Leibowitch M; Escande JP
    Presse Med; 1984 Nov; 13(40):2433-6. PubMed ID: 6239222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The molecular characterization of clinical isolates from Indian Kala-azar patients by MLEE and RAPD-PCR.
    Manna M; Majumder HK; Sundar S; Bhaduri AN
    Med Sci Monit; 2005 Jul; 11(7):BR220-7. PubMed ID: 15990683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kala-azar elimination programme in India.
    Dhillon GP; Sharma SN; Nair B
    J Indian Med Assoc; 2008 Oct; 106(10):664, 666-8. PubMed ID: 19552101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-kala-azar dermal leishmaniasis and visceral leishmaniasis in a child--or is it para-kala-azar dermal leishmaniasis?
    Mendiratta V; Chander R
    Int J Dermatol; 2009 Sep; 48(9):1027-8. PubMed ID: 19703001
    [No Abstract]   [Full Text] [Related]  

  • 39. Risk factors for Indian kala-azar.
    Ranjan A; Sur D; Singh VP; Siddique NA; Manna B; Lal CS; Sinha PK; Kishore K; Bhattacharya SK
    Am J Trop Med Hyg; 2005 Jul; 73(1):74-8. PubMed ID: 16014837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Visceral leishmaniasis (kala-azar) in Gujarat.
    Vaishnav VP; Shah CP; Shah BR; Sanghavi NG; Dave JM
    J Indian Med Assoc; 1970 Jan; 54(2):66-70. PubMed ID: 5418149
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.